E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy

Breast Cancer. 2001;8(4):285-93. doi: 10.1007/BF02967526.


In the late 1980s, we have shown that the E1A gene can downregulate HER-2/neu overexpression, thus reversing the tumorigenic and metastatic phenotype. Further, E1A can function as a tumor suppressor gene by inducing apoptosis and inhibiting metastasis. At The University of Texas M. D. Anderson Cancer Center, we have been investigating the adenovirus type 5 E1A gene as a potential therapeutic gene in breast and ovarian cancer since 1995 by using cationic liposome as gene delivery system. In this chapter, we recount our development of E1A as a therapeutic gene.

Publication types

  • Comparative Study
  • Lecture

MeSH terms

  • Adenovirus E1A Proteins / administration & dosage*
  • Adenovirus E1A Proteins / genetics*
  • Animals
  • Breast Neoplasms / genetics
  • Breast Neoplasms / therapy*
  • Clinical Trials, Phase I as Topic
  • Disease Models, Animal
  • Female
  • Follow-Up Studies
  • Genes, Tumor Suppressor / physiology*
  • Genetic Therapy / methods*
  • Humans
  • Mice
  • Oncogene Proteins, Viral / administration & dosage*
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / therapy*
  • Sensitivity and Specificity


  • Adenovirus E1A Proteins
  • Oncogene Proteins, Viral